BioNanomatrix's previous investors, KT Venture Group, the corporate venturing unit of semiconductor equipment company KLA-Tencor, and non-profit research group Battelle Memorial Institute through its corporate venturing units Battelle Ventures and Innovation Valley Partners, reinvested in the $23.3m B round.

BioNanomatrix, a US-based provider of analysis of the human genome, has raised $23.3m in its series B round.

BioNanomatrix’s previous investors, KT Venture Group, the corporate venturing unit of semiconductor equipment company KLA-Tencor, and non-profit research group Battelle Memorial Institute through its corporate venturing units Battelle Ventures and Innovation Valley Partners, reinvested in the B round.

The round was led by venture capital firm Domain Associates and joined by family office Gund Investment.

In March 2008, Battelle Ventures, led BioNanomatrix’s $5.1m series A round, and was joined by KT Venture Group and seed investors Ben Franklin Technology Partners and 21Ventures.

The seed round closed in May 2006.